Biotech

---

As financial advisors to Pilatus Biosciences, we support a pioneering biotech company developing first-in-class antibodies and bifunctional proteins that reprogram the immune microenvironment. Pilatus Biosciences focuses on novel immunotherapies for cancer and immune-related diseases.

Our advisory role with CanVirex involves a biotech innovator developing oncolytic measles virus vectors for cancer immunotherapy and vaccine applications. Originating from Heidelberg University Hospital, the company’s technology enables genetically engineered viruses to selectively infect and destroy tumors.

We advise Luciole Medical, a Swiss medtech company advancing brain monitoring technology for critical care and surgical settings. Its minimally invasive probes and non-invasive sensors provide real-time insights into cerebral oxygenation and blood flow.

In our work with Nano-Nose, we support a deep-tech venture developing nanosensor platforms capable of detecting trace biomarkers in breath and air samples. Their technology aims to enable early disease detection and environmental diagnostics with high sensitivity and precision.

As financial advisors to Biospectal SA, we partner with a Swiss digital-health innovator whose OptiBP™ app turns smartphones into clinically validated, cuff-free blood pressure monitors—bringing accessible cardiovascular care to users worldwide.

As advisors to Adiposs SA, we collaborate with a Geneva-based biotech developing ImageBAT®, the first contrast agent enabling non-invasive CT imaging of brown adipose tissue. The technology helps identify treatment responses earlier in cancer and metabolic diseases.